Loading...
Vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors and the immune checkpoint inhibitors ipilimumab and nivolumab are broadly used for management of metastatic clear-cell renal cancers; nonetheless, most patients with metastatic renal cancer still die of disease progression. Investigators conducted a manufacturer-sponsored phase III trial in which patients with previously untreated advanced renal-cell carcinoma were randomized to receive sunitinib or a combination of pembrolizumab (a programmed death 1 [PD-1] inhibitor) plus axitinib; dosing cycles were 4 weeks on/2 weeks off. The primary endpoints were overall survival and progression-free survival (PFS) in the intention-to-treat population; objective re…